E K Mulholland

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. ncbi request reprint Prevention of otitis media by vaccination
    Fiona Russell
    Centre for International Child Health, University of Melbourne, Royal Children s Hospital, Flemington Road, Parkville, Victoria 3051, Australia
    Drugs 62:1441-5. 2002
  2. ncbi request reprint Global burden of acute respiratory infections in children: implications for interventions
    Kim Mulholland
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Parkville, Victoria, Australia
    Pediatr Pulmonol 36:469-74. 2003
  3. ncbi request reprint Evaluation of vaccines to prevent childhood pneumonia: lessons relevant to planning tuberculosis vaccine trials
    K Mulholland
    Division of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 30:S206-9. 2000
  4. ncbi request reprint Conjugate pneumococcal vaccines: an overview
    E K Mulholland
    Department of Paediatrics, University of Melbourne, Vic
    Med J Aust 173:S48-50. 2000
  5. ncbi request reprint Haemophilus influenzae type b infection in children in Pacific countries
    J R Carapetis
    Centre for International Child Health, University of Melbourne, Royal Children s Hospital, Melbourne, Australia
    Pac Health Dialog 11:79-83. 2004
  6. pmc Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Melbourne, Australia
    Vaccine 29:4499-506. 2011
  7. pmc Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Melbourne, Victoria, Australia
    Vaccine 28:3341-9. 2010
  8. pmc Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Victoria, Australia
    Clin Vaccine Immunol 17:1970-6. 2010
  9. doi request reprint Reduction of meningitis and impact on under-5 pneumonia after introducing the Hib vaccine in the Kingdom of Tonga
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Victoria, Australia
    Ann Trop Paediatr 29:111-7. 2009
  10. pmc Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Melbourne, Australia
    Vaccine 28:3086-94. 2010

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Prevention of otitis media by vaccination
    Fiona Russell
    Centre for International Child Health, University of Melbourne, Royal Children s Hospital, Flemington Road, Parkville, Victoria 3051, Australia
    Drugs 62:1441-5. 2002
    ..A more substantial reduction in the burden of OM in childhood would require a combination of vaccines that are effective against the bacterial and viral pathogens involved and that can be administered early in infancy...
  2. ncbi request reprint Global burden of acute respiratory infections in children: implications for interventions
    Kim Mulholland
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Parkville, Victoria, Australia
    Pediatr Pulmonol 36:469-74. 2003
    ..For reasons outlined in this paper, great caution must be exercised before using existing pneumonia burden estimates to predict mortality savings that may accompany the introduction of these vaccines into developing countries...
  3. ncbi request reprint Evaluation of vaccines to prevent childhood pneumonia: lessons relevant to planning tuberculosis vaccine trials
    K Mulholland
    Division of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Clin Infect Dis 30:S206-9. 2000
    ..The existence of bacille Calmette-Guérin (BCG) complicates future trials, and such trials should take into account possible nonspecific effects of BCG in addition to its effect on tuberculosis...
  4. ncbi request reprint Conjugate pneumococcal vaccines: an overview
    E K Mulholland
    Department of Paediatrics, University of Melbourne, Vic
    Med J Aust 173:S48-50. 2000
    ..Studies of the burden of pneumococcal disease as well as program support are needed to assist developing countries to introduce these expensive vaccines...
  5. ncbi request reprint Haemophilus influenzae type b infection in children in Pacific countries
    J R Carapetis
    Centre for International Child Health, University of Melbourne, Royal Children s Hospital, Melbourne, Australia
    Pac Health Dialog 11:79-83. 2004
    ..The high Hib disease burden and the relative cost-effectiveness of Hib vaccine, make the introduction of Hib vaccine a good investment for PICs costing US$ 1,000-10,000 for each death prevented - ignoring treatment cost savings...
  6. pmc Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Melbourne, Australia
    Vaccine 29:4499-506. 2011
    ....
  7. pmc Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Melbourne, Victoria, Australia
    Vaccine 28:3341-9. 2010
    ....
  8. pmc Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Victoria, Australia
    Clin Vaccine Immunol 17:1970-6. 2010
    ..By the age of 17 months, NVT carriage rates were similar for all groups. 23vPPS had no impact on carriage, despite the substantial boosts in antibody levels...
  9. doi request reprint Reduction of meningitis and impact on under-5 pneumonia after introducing the Hib vaccine in the Kingdom of Tonga
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Victoria, Australia
    Ann Trop Paediatr 29:111-7. 2009
    ..To document the impact of Hib vaccine on Haemophilus influenzae (Hi) invasive disease, meningitis and inpatient pneumonia in children under 5 in the Kingdom of Tonga...
  10. pmc Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Melbourne, Australia
    Vaccine 28:3086-94. 2010
    ..By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group...
  11. pmc Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Melbourne, Australia
    Vaccine 29:535-44. 2011
    ..A single dose improved OPA compared with the unvaccinated group. PPV-23 significantly improved OPA for all serotypes tested but in general, was associated with diminished responses following re-challenge...
  12. pmc Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine
    F M Russell
    Centre for International Child Health, Murdoch Childrens Research Institute, Department of Paediatrics, University of Melbourne, Victoria, Australia
    Vaccine 27:5685-91. 2009
    ..Although GMC following three doses are higher than after two doses, the differences were small. A single dose may offer some protection for most serotypes...
  13. ncbi request reprint Recent advances in pneumococcal vaccination of children
    Fiona M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Parkville, Melbourne, Australia
    Ann Trop Paediatr 24:283-94. 2004
    ..In addition, other vaccination strategies such as maternal and neonatal immunisation and combinations of fewer doses of the PCV combined with an early dose of the cheaper pneumococcal polysaccharide vaccine need to be assessed further...
  14. ncbi request reprint Pneumococcal nasopharyngeal carriage and patterns of penicillin resistance in young children in Fiji
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Melbourne, Australia
    Ann Trop Paediatr 26:187-97. 2006
    ..We set out to document pneumococcal nasopharyngeal carriage and associated risk factors, antimicrobial resistance and serotypes in healthy children in Fiji...
  15. pmc As a bacterial culture medium, citrated sheep blood agar is a practical alternative to citrated human blood agar in laboratories of developing countries
    F M Russell
    Department of Paediatrics, Centre for International Child Health, University of Melbourne, Melbourne, Australia
    J Clin Microbiol 44:3346-51. 2006
    ..CSB MHA may be suitable for use for the susceptibility testing of S. pneumoniae...
  16. pmc Chest X-ray-confirmed pneumonia in children in Fiji
    H C Magree
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Parkville, Victoria 3052, Australia
    Bull World Health Organ 83:427-33. 2005
    ..To calculate the incidence and document the clinical features of chest X-ray- (CXR-) confirmed pneumonia in children aged between 1 month and 5 years living in Greater Suva, Fiji...
  17. ncbi request reprint High incidence of Haemophilus influenzae type b infection in children in Pacific island countries
    F M Russell
    Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children s Hospital, Parkville, Melbourne, Australia
    Clin Infect Dis 37:1593-9. 2003
    ....
  18. ncbi request reprint A randomised trial of a Haemophilus influenzae type b conjugate vaccine in a developing country for the prevention of pneumonia--ethical considerations
    K Mulholland
    Vaccines and Other Biologicals, World Health Organization, Geneva, Switzerland
    Int J Tuberc Lung Dis 3:749-55. 1999
    ..After a delay of 17 months following the completion of the trial, national Hib vaccination was started in The Gambia in 1997 using vaccine provided by a donation from industry...
  19. pmc Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents
    S F La Vincente
    Centre for International Child Health, Murdoch Childrens Research Institute, Royal Children s Hospital, Flemington Road, Parkville, Vic, 3052, Australia
    BMC Public Health 15:1257. 2015
    ....
  20. ncbi request reprint Strategies for the control of pneumococcal diseases
    K Mulholland
    Vaccine Research and Development, Global Programme for Vaccines and Immunization, World Health Organization, Geneva, Switzerland
    Vaccine 17:S79-84. 1999
    ..Polysaccharide vaccines probably have a role in protecting the elderly from pneumococcal disease, especially those at high risk. The potential role of conjugate vaccines in infants is unclear...
  21. pmc Long-term morbidity and mortality following hypoxaemic lower respiratory tract infection in Gambian children
    T E West
    Medical College of Virginia, Richmond, USA
    Bull World Health Organ 77:144-8. 1999
    ..Survival depends more on nutritional status than on having been hypoxaemic. Investment in oxygen therapy appears justified, and efforts should be made to improve nutrition in malnourished children with pneumonia...
  22. pmc Use of simple clinical signs to predict pneumonia in young Gambian children: the influence of malnutrition
    A G Falade
    Medical Research Council Laboratories, Banjul The Gambia
    Bull World Health Organ 73:299-304. 1995
    ..As the latter are a high-risk group, we should like to recommend that children with malnutrition who present with a cough, fast breathing or difficult breathing should be treated with antibiotics...